Business Wire1mon
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR ...
Hosted on MSN26d
Vertex's Pain Drug: Big Pharma's Next Major Success?
One notable example is the partnership with Zai Lab to develop and commercialize povetacicept in mainland China, Hong Kong, Macau, Taiwan, and Singapore. This collaboration provides Vertex with ...
The Motley Fool27d
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.
Nasdaq1mon
Zai Lab, Vertex Ink Stategic Deal For Povetacicept In China And The Broader Area
announced an exclusive collaboration and licensing agreement for the development and commercialization of Vertex's investigational drug, Povetacicept or pove, in mainland China, Hong Kong ...
Business Wire1mon
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR ...